CCN3 and neoplasm: To further clarify the role of ERK signaling activated by CCN3 in the migration of LX2, Sorafenib or U0126 combined with CCN3 exhibited decreased migration (39.50 ± 3.30 vs. 13.51 ± 4.93, p = 0.0002; 39.50 ± 3.30 vs. 19.01 ± 4.32, p = 0.0011) and proliferation of LX2 with down-regulated ERK signaling (Fig. 4b, e). In this section, we proved only when HSC cells enter the tumor tissues can they play a promoting role in cancer, and enhanced migration and proliferation of HSC were relating to ERK signaling pathway after treated by CCN3.